title: [Acquired factor V inhibitor: etiology, bleeding risk and therapeutic management with regard to three cases].
abstract: BACKGROUND
  Acquired factor V inhibitor is rare and clinical symptoms are quite variable. Bleeding is the leading symptom but some patients are asymptomatic. Several diseases or conditions are associated with factor V inhibitors. Various treatments have been attempted but randomized or prospective trials are not available.
  
  
  METHODS
  Here we report three cases of acquired factor V inhibitor. These reports highlight the clinical variability of this disorder. Pathogenesis and therapy with reference to the literature are discussed.
  
  
  CONCLUSIONS
  Factor V inhibitors are rare and associated to several diseases or conditions. Pathogenesis is still unclear except in patients exposed to bovine thrombin. The majority of the cases developed after surgery. In a few cases there is an association to a malignant or autoimmune disease. Plasmapheresis and platelet transfusions might be the best treatment in case of severe bleeding. High-dose intravenous immunoglobulin infusions have been used successfully in some cases and we report here their efficacy in two cases.
authors.affiliation: Service de médecine interne, hôpital de la Conception, 13385 Marseille, France. nschleinitz@mail.ap-hm.fr
authors.forename: N
authors.initials: N
authors.lastname: Schleinitz
authors.forename: V
authors.initials: V
authors.lastname: Veit
authors.forename: D
authors.initials: D
authors.lastname: Chouquet
authors.forename: V
authors.initials: V
authors.lastname: Seux
authors.forename: D
authors.initials: D
authors.lastname: Arnoux
authors.forename: D
authors.initials: D
authors.lastname: Mokart
authors.forename: B
authors.initials: B
authors.lastname: Lelong
authors.forename: M C
authors.initials: MC
authors.lastname: Alessi
authors.forename: G
authors.initials: G
authors.lastname: Kaplanski
authors.forename: J R
authors.initials: JR
authors.lastname: Harlé
mesh_terms: D000368:Aged; D001778:Blood Coagulation Disorders / Q000209:etiology*; D005165:Factor V / Q000037:antagonists & inhibitors*; D005260:Female; D006470:Hemorrhage / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D012307:Risk Factors
chemical_list: D005165:Factor V